The purpose of this study is to establish clinical proof-of-concept of effectiveness and to evaluate dose responses of the study drug in patients with IgAN. LNP023 is a new compound that is meant to stop inflammation in the body. Patients will be involved in the trial for about 3 months, and will need to do regular labwork.
How To Contact a Study Center:
- Visit KidneyHealthGateway.com to see if you might be eligible and to contact a study site near you